Search

Your search keyword '"ddi"' showing total 49 results

Search Constraints

Start Over You searched for: Descriptor "ddi" Remove constraint Descriptor: "ddi" Topic drug interactions Remove constraint Topic: drug interactions
49 results on '"ddi"'

Search Results

1. Predict the Drug-Drug Interaction of a Novel PI3Kα/δ Inhibitor, TQ-B3525, and Its Two Metabolites Using Physiologically Based Pharmacokinetic Modeling.

2. PTB-DDI: An Accurate and Simple Framework for Drug-Drug Interaction Prediction Based on Pre-Trained Tokenizer and BiLSTM Model.

3. Notable drug-drug interaction between omeprazole and voriconazole in CYP2C19 *1 and *2 (rs4244285, 681G>A) alleles in vitro .

4. Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments.

5. Drug-drug interaction between diclofenac and gamma-hydroxybutyric acid.

6. Potential drug-drug interactions associated with clinical and laboratory findings at hospital admission.

7. 2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists.

8. Drug-drug interaction prediction using PASS.

9. A UHPLC-MS/MS method coupled with liquid-liquid extraction for the quantitation of phenacetin, omeprazole, metoprolol, midazolam and their metabolites in rat plasma and its application to the study of four CYP450 activities.

10. Prediction of the effect of voriconazole on the pharmacokinetics of non-steroidal anti-inflammatory drugs.

11. Quantitative in vitro phenotyping and prediction of drug interaction potential of CYP2B6 substrates as victims.

12. Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications.

13. Validation of a total IC 50 method which enables in vitro assessment of transporter inhibition under semi-physiological conditions.

14. QSAR Modeling and Prediction of Drug-Drug Interactions.

15. Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method.

16. Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo.

17. A P-gp vesicular transport inhibition assay - optimization and validation for drug-drug interaction testing.

18. Beyond cytotoxic potency: disposition features required to design ADC payload.

19. Drug–Drug Interaction Potential of Mavacamten with Oral Contraceptives: Results from a Clinical Pharmacokinetic Study and a Physiologically Based Pharmacokinetic Model.

20. Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants.

21. Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET‐dysregulated solid tumours.

22. Building a Human Physiologically Based Pharmacokinetic Model for Aflatoxin B1 to Simulate Interactions with Drugs.

23. A phase 1, open-label, randomized drug–drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.

24. Development of Physiology Based Pharmacokinetic Model to Predict the Drug Interactions of Voriconazole and Venetoclax.

25. JBP485, A Dual Inhibitor of Organic Anion Transporters (OATs) and Renal Dehydropeptidase-I (DHP-I), Protects Against Imipenem-Induced Nephrotoxicity.

26. PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid.

27. Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates.

28. The Influence of Different Triazole Antifungal Agents on the Pharmacokinetics of Cyclophosphamide.

29. Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation.

30. Investigation of drug -drug interactions status, in University-Based Pharmacies, in Lorestan, IRAN.

31. Unremarkable impact of Oatp inhibition on the liver concentration of fluvastatin, lovastatin and pitavastatin in wild-type and Oatp1a/1b knockout mouse.

32. Near Field Communication Detection System for Drug-Drug Interactions.

33. Quantitative <italic>in vitro</italic> phenotyping and prediction of drug interaction potential of CYP2B6 substrates as victims.

34. Clinical relevancy and determinants of potential drug–drug interactions in chronic kidney disease patients: results from a retrospective analysis.

35. DRUG-DRUG INTERACTION (DDI) TOOLS - USEFUL VERSUS MANDATORY IN THE MANAGEMENT OF DIFFICULT TO TREAT PATIENTS WITH CHRONIC HCV INFECTION.

36. Prediction of drug–drug interactions with carbamazepine-10,11-epoxide using a new in vitro assay for epoxide hydrolase inhibition.

37. Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-( N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778 875), a subtype selective agonist of the peroxisome proliferator-activated receptor alpha

38. Modeling Chemical Interaction Profiles: II. Molecular Docking, Spectral Data-Activity Relationship, and Structure-Activity Relationship Models for Potent and Weak Inhibitors of Cytochrome P450 CYP3A4 Isozyme.

39. Application of PBPK modelling in drug discovery and development at Pfizer.

40. Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug--drug interaction to support regulatory submissions.

41. Calcein assay: a high-throughput method to assess P-gp inhibition.

42. Extrapolating in vitro metabolic interactions to isolated perfused liver: Predictions of metabolic interactions between R-bufuralol, bunitrolol, and debrisoquine.

43. Concomitant use of policosanol and benzodiazepines in older patients.

44. Mechanistically Coupled PK (MCPK) Model to Describe Enzyme Induction and Occupancy Dependent DDI of Dabrafenib Metabolism.

45. Mathematical Modelling of the Molecular Mechanisms of Interaction of Tenofovir with Emtricitabine against HIV.

46. The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant.

47. In Silico Prediction of Drug–Drug Interactions Mediated by Cytochrome P450 Isoforms.

48. Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications

49. Avoiding concomitant prescription of drugs with a potential for interaction: mission impossible?

Catalog

Books, media, physical & digital resources